Skip to main content

Table 4 Adverse events by preferred term, regardless of relationship to everolimus

From: Assessing the outcomes of everolimus on renal angiomyolipoma associated with tuberous sclerosis complex in China: a two years trial

n(%)   Everolimus (N = 18)
All grades Grade 3 Grade 4 Grade 5
Mucositis oral 18(100%) 2(11.1%)
Irregular menstruation 11(91.7%) 3(25.0%)
Abdominal pain 14(77.8%) 1(5.6%)
Hypertriglyceridemia 13(72.2%)
Headache 12(66.7%)
Diarrhea 11(61.1%)
Upper respiratory infection 10(55.6%)
Proteinuria 9(50%) 1(5.6%)
Malaise 9(50%)
Rash acneiform 8(44.4%)
Cholesterol high 8(44.4%)
Fever 6(33.3%)
Urinary tract infection 5(27.8%)
Hematuria 5(27.8%)
Alkaline phosphatase increased 5(27.8%)
Constipation 4(22.2%)
GGT increased 4(22.2%)
Hypophosphatemia 4(22.2%)
Seizures 3(16.7%)
Pneumonitis 2(11.1%) 1(5.6%) 1(5.6%)
Vomiting 2(11.1%) 1(5.6%)
Lymphocyte count decreased 2(11.1%)
Anemia 2(11.1%)
Renal hemorrhage 1(5.6%) 1(5.6%)
Neutrophil count decreased 1(5.6%)
Hyperuricemia 1(5.6%)
Creatinine increased 1(5.6%)